Mood disruption during the menopause transition is frequently underestimated and undertreated — often dismissed as incidental to hormonal change rather than a direct biological consequence of estrogen fluctuation. A real-world dataset now offers clinically meaningful evidence that systemic hormone therapy (HT) may address psychological symptoms well beyond its FDA-approved vasomotor indications, potentially reshaping how prescribers and patients frame the treatment conversation.
Drawing on 260 HT-naive patients seen at an urban academic menopause center between 2023 and 2025, researchers tracked Menopause Rating Scale (MRS) psychological subdomain scores — covering depressive mood, irritability, anxiety, and mental exhaustion — before and after initiating transdermal estradiol (used by 96.5% of participants). At a mean follow-up of 4.5 months, the proportion of women with severe mood scores dropped from 62.3% to 24.6%, a statistically significant reduction (P<0.001). Crucially, those with the most severe baseline symptoms showed the greatest absolute improvement (mean change: −3.85). Treatment response was consistent regardless of psychiatric history, menopausal stage, age, or concurrent antidepressant use — a finding that broadens the potential candidate pool.
The biological plausibility is solid: estrogen modulates serotonergic and dopaminergic pathways, and the perimenopausal window — characterized by erratic estradiol fluctuation rather than simply low levels — is a recognized neurobiological vulnerability period. What makes this dataset notable is its real-world design and the high baseline burden of psychiatric comorbidity (51% had anxiety or depression history; 24% were already on antidepressants), yet HT still delivered measurable benefit across subgroups. However, important limitations apply: the retrospective observational design cannot establish causation, the follow-up period is short at 4.5 months, there is no placebo control, and self-reported MRS scores carry inherent subjectivity. The cohort is also drawn from a single academic center, limiting generalizability. This study is best characterized as confirmatory and clinically directional — it reinforces emerging evidence that HT's mood benefit warrants formal randomized investigation, rather than settling the question definitively.
